Enrollment Opens for Clinical Trial of a New Drug for Crohn’s Disease

Dobrobut Medical Network has announced patient enrollment for an international Phase clinical trial evaluating a new oral medication for the treatment of moderate to severe Crohn’s disease. This is the second Crohn’s disease clinical trial currently conducted within the network, alongside another study investigating an innovative biological therapy.

The purpose of the study is to evaluate the efficacy and safety of the new oral medication and determine whether it can provide better control of intestinal inflammation and disease symptoms.

The study has been approved by the State Expert Center of the Ministry of Health of Ukraine and the Ethics Committee and is conducted in accordance with international Good Clinical Practice (GCP) standards. Participants' rights, safety, and confidentiality remain the highest priority throughout the study.

Participants receive free access to the investigational once-daily oral capsule, consultations with study physicians, laboratory and diagnostic examinations, including colonoscopy under medical sedation. Free transportation within Kyiv and the Kyiv region is also provided.

"Crohn’s disease is a chronic condition that significantly affects a person's quality of life. Although modern treatment options are available, some patients fail to achieve sustained disease control or gradually lose their response to therapy. That is why the development of new treatment options remains critically important. Clinical trials allow researchers to evaluate promising therapies while giving patients access to innovative treatment under the continuous supervision of an experienced research team," said Kseniia Sekretna, Head of the Clinical Research Center at Dobrobut Medical Network.

Eligible participants may include adults aged 18 to 75 with a confirmed diagnosis of Crohn’s disease who have moderate to severe symptoms (such as abdominal pain, diarrhea, and other manifestations) and whose previous treatment has been ineffective, has lost effectiveness over time, or has caused intolerance.

Participation is subject to clearly defined safety criteria. Patients with certain coexisting medical conditions, active severe infections, specific types of previous cancer, or other conditions specified in the study protocol are not eligible.

Before enrollment, all candidates undergo a screening process. The research team reviews medical records, assesses eligibility, and recommends the most appropriate clinical trial. Final enrollment is confirmed only after a comprehensive medical evaluation. All potential risks and uncertainties are thoroughly explained before participants sign the informed consent form.

For more information or to schedule a preliminary consultation, please call +380 67 150 29 87 (Olha Zhmurko, Clinical Research Manager at Dobrobut Medical Network) or contact the team via messaging apps.